News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Enzon (ENZN) And Pharmagene Announce Agreement To Develop PEGylated Secretin For Cystic Fibrosis


10/19/2005 5:11:24 PM

Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) and Pharmagene plc (LSE:PGN) announced today they have signed an agreement for the development of a long-acting version of Pharmagene's drug candidate, PGN0052. PGN0052 is a peptide hormone that is initially being investigated as a treatment for cystic fibrosis and may have additional applications for other respiratory disorders.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES